We're moving to rndsystems.com. Come with us!

After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.

CD20

Unlocking the Potential of Biosimilars in Immuno-Oncology

Antigen-loss relapse after successful CAR-T therapy; What do we do now?

Acute lymphoblastic leukemia disease bioinformatics

By Jacqueline Carrico, BS, MD

CD20 (Cluster of differentiation 20, Membrane-spanning 4-domains subfamily A member 1 (MS4A1), CVID5, B-lymphocyte surface antigen B1)

CD20 is a human B-lymphocyte surface molecule that spans the membrane four times and is expressed on both normal and malignant cells. The CD20 antigen displays a unique expression pattern among hematopoietic cells - it is present on human pre B-lymphocytes and B-lymphocytes at all stages of maturation (except for plasma cells). Low CD20 antigen expression levels have been detected on normal T-lymphocytes. It functions as a B-cell activation receptor and B-lymphocyte development and differentiation agent, presumably through modulating intracellular calcium levels.